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Background: Side effects, or the adverse effects of drugs, contain important clinical phenotypic information that
may be useful in predicting novel or unknown targets of a drug. It has been suggested that drugs with similar
side-effect profiles may share common targets. The diagnostic class, Major Depressive Disorder, is increasingly
viewed as being comprised of multiple depression subtypes with different biological root causes. One ‘type’ of
depression generating substantial interest today focuses on patients with high levels of inflammatory burden,
indicated by elevated levels of C-reactive proteins (CRP) and pro-inflammatory cytokines such as interleukin 6 (IL-6). It
has been suggested that drugs targeting the immune system may have beneficial effect on this subtype of depressed
patients, and several studies are underway to test this hypothesis directly. However, patients have been treated with
both anti-inflammatory and antidepressant compounds for decades. It may be possible to exploit similarities in clinical
readouts to better understand the antidepressant effects of immune-related drugs.
Methods: Here we explore the space of approved drugs by comparing the drug side effect profiles of known
antidepressants and drugs targeting the immune system, and further examine the findings by comparing the
human cell line expression profiles induced by them with those induced by antidepressants.
Results: We found 7 immune-modulators and 14 anti-inflammatory drugs sharing significant side effect profile
similarities with antidepressants. Five of the 7 immune modulators share most similar side effect profiles with
antidepressants that modulate dopamine release and/or uptake. In addition, the immunosuppressant rapamycin
and the glucocorticoid alclometasone induces transcriptional changes similar to multiple antidepressants.
Conclusions: These findings suggest that some antidepressants and some immune-related drugs may affect
common molecular pathways. Our findings support the idea that certain medications aimed at the immune system
may be helpful in relieving depressive symptoms, and suggest that it may be of value to test immune-modulators for
antidepressant-like activity in future proof-of-concept studies.
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Major Depressive Disorder (MDD) is a disabling psychiatric
disease with high life time prevalence (16.2 % among US
adults) [1]. Despite advances in the treatments of MDD,
30-40 % patients are resistant to available antidepressant
medications [2]. Therefore, searching for the underlying
cause of treatment-resistance and finding new treatments
for depression has become a priority in psychiatric research.
One intriguing hypothesis suggests that pro-inflammatory
neuroactive cytokines may play a significant role in the
pathogenesis of at least a subgroup of MDD patients [3].
Multiple studies have shown that some MDD patients have
elevated serum levels of pro-inflammatory biomarkers, such
as Interleukin 1 (IL-1), Interleukin 6 (IL-6), Tumor Necrosis
Factor alpha (TNF-α), and C-reactive Protein (CRP) com-
pared to healthy controls [4–6]. Furthermore, prolonged
interferon-α treatment can induce depression, indicating a
causal relationship between immune response and onset of
depression [7]. Interestingly, MDD patients resistant to
treatment with selective serotonin re-uptake inhibitors
(SSRI) were shown to have higher IL-6 and TNF-α levels
than healthy controls and euthymic patients who were
formerly SSRI-resistant [8].
The crosstalk between immune response and mood
changes indicated by these studies raise the possibility of
treating depressive symptoms with immune-modulators
or anti-inflammatory medications. A double-blind, placebo-
controlled, randomized clinical study demonstrated that
treatment with TNF-α antagonist infliximab reduces de-
pressive symptoms in treatment-resistant MDD patients
having baseline high-sensitivity CRP (hs-CRP) concentra-
tion greater than 5 mg/L but not in patients with lower
baseline hs-CRP, suggesting the potential of using immune-
modulators to treat depressive symptoms in certain sub-
group of MDD patients [9]. Another immune modulator,
ustekinumab, targeting IL-12/23, is reported to significantly
improve symptoms of depression and anxiety of patients
with moderate-to-severe psoriasis in a randomized, double-
blinded, placebo-controlled trial [10]. Several clinical
trials have also shown that adding nonsteroidal anti-
inflammatory drugs (NSAIDs) such as cyclooxygenase
(COX) inhibitors to SSRI medication helps to reduce
the severity of depression, indicating that anti-inflammatory
drugs could augment antidepressant effects [11, 12].
However, another large-scale study evaluating the effi-
cacy of NSAIDs as mono-therapy for late-life depres-
sion in ~2500 elderly adults showed no significant
effect in reducing depressive symptoms compared with
placebo [13]. Yet a recent meta-analysis pooling results
from all available randomized trials testing NSAIDs
and cytokine inhibitors as antidepressants showed that
the pooled effect estimate suggested anti-inflammatory
treatment reduced depressive symptoms compared with
placebo [14].Overall, these results support the idea that treatment
targeting the elevated levels of immune/inflammatory re-
sponse in some MDD patients could relieve depressive
symptoms. However, more clinical studies on additional
immune therapies are needed to characterize the efficacy
of different treatments. This could be both costly and
time-consuming. Therefore, a systematic in silico survey
of the potential of repurposing immune-related medica-
tion to treat MDD patients could help ranking these al-
ternative therapies before testing them in animal models
or clinical studies. Several such methods have been pro-
posed, showing different levels of success. One type of
method is based on the hypothesis that similar ligands
are likely to bind similar proteins and makes predictions
of novel drug-target interactions using compound struc-
ture similarity, protein sequences of targets and known
compound-protein interactions [15–18]. However such a
method will miss cases where a common biological
pathway or network may be perturbed, leading to a com-
mon biological effect, despite different drugs targeted
different binding pockets or even different proteins in the
network (e.g. targeting IL-6 vs. IL-6 receptor). Another
promising approach is to use pharmacological information
such as similarities in drug induced transcriptional expres-
sion signatures [19]; while this generates interesting novel
findings, it is unclear whether insights gleaned in a cell-
line will translate to patients in vivo. For example, two
drugs with similar in vitro transcriptional expression
signatures, in the human body may be concentrating in
different organs, and interacting with different cell
types, ultimately resulting in different biological outcomes.
A recent strategy applied has focused on drug side effect
profile similarities [20, 21], based on the notion than we
may not know all of the biological effects of our known
compounds, but similarities in mechanism within the
human environment may be revealed by similarities in
side effects. This method is especially useful when
drugs have limited structure similarities and may not
share direct targets, which is often the case between
small molecular antidepressants and large molecule
immune-modulators. In this study, we conduct an in
silico survey to identify promising candidates for repur-
posing immune-modulators and anti-inflammatory drugs
as antidepressant by first exploring the space of side effect
similarities between these drugs and then searching for
additional supporting evidence by comparing transcrip-
tional expression profiles induced by these drugs in
human cell lines.
Methods
Drug side effect data
The side effects of 996 marketed drugs were obtained
from the Side Effect Resource database (SIDER 2: http://
sideeffects.embl.de/) [22]. This database extracted the
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serts automatically and then standardized them using
the MedDRA dictionary (version 14.0). Side effects of 9
additional drugs of interest (flupirtine, dextromethorphan,
phencyclidine hydrochloride, piracetam, tocilizumab,
siltuximab, infliximab, golimumab, ustekinumab) were
extracted manually from their labels. All except 9 side
effect terms from these drugs had corresponding key-
words used in SIDER2. The side effect profiles of these
9 drugs were combined together with the SIDER2 data
in our analysis. The side effect profile of each drug is
represented by a binary vector X = (x1, x2, …xK)
T, where
each side effect term is coded 1 or 0 to represent their
presence or absence in the drug label. T is the total
number of side effects, which is 4201 in our analysis.
Combining all the side effect profile vectors of 1005
(996 SIDER2 + 9 drugs of interest) drug, we represent
the drug by side effect relationship in a 1005 x 4201
binary matrix.
Drug side effect profile similarity analysis
To evaluate the similarity between side effect profiles of
a pair of drugs represented by two binary vectors X and
X’, we calculated the weighted cosine correlation coeffi-
cient as described by Takarabe, etc. [21]:














where wk is the weight function for the kth side effect
term defined as
wk ¼ exp −d2k=σ2h2
 
; k ¼ 1; 2;…K
where dk is the frequency of the kth side effect term in
the data, and K is the total number of side effect terms
in the data, σ is the average frequency for all the side ef-
fect terms in the data and h is a parameter (set to 1 in
this study). This weight function gives higher weight to
the less common side effects than the more common
ones, because rare side effects provide more information
in terms of the specific clinical effects of the drugs.
The significance of the pair-wise similarity score is es-
timated by comparing the original score with scores gen-
erated by shuffling the side effect labels randomly 1000
times. To focus on drug pairs that may share substantial
common on or off-target effects, only drug pairs having
similarity score with random shuffling P-value < 0.05 and
sharing at least 3 uncommon side effects (weight ≥ 0.1)
were retained for further analysis. We require each drug
pairs to share at least 3 uncommon side effects in order to
increase the likelihood that the drugs of interest are influ-
encing common biological pathways.Out of the 1005 drugs studied, we identified 30 antide-
pressants based on the KEGG Drug database annotation
(http://www.genome.jp/kegg/drug/). These included drugs
approved as antidepressants, drugs used as augments with
other antidepressants, as well as drugs with accumulating
evidence of antidepressant activity but not approved as an-
tidepressants yet. These 30 drugs are listed in Table 1.
Drugs that had side effect profiles similar to one or more of
these 30 antidepressants according to their similarity scores
calculated as above were selected.
Connectivity map analysis
The Connectivity Map database (https://www.broadinsti-
tute.org/cmap/) provides a collection of reference genome-
wide transcriptional expression profiles from cultured
human cells treated with bioactive small molecules, and
a pattern-matching tool that could help discover func-
tional connections between drugs, genes and diseases
by detecting common gene-expression changes [19]. In
our analysis, we queried the Connectivity Map database
for drugs whose expression signatures are similar to the
immune-related drugs sharing side effect similarities
with antidepressants. In CMAP, the expression profiles
are organized as instances labeled with unique instance
identification numbers. Each instance contains a treated
and control cell pair and the list of probe sets ordered by
their level of differential expression between the treatment
and control pair. For drugs with expression signatures in
the database, we first selected the instances with the same
dosage, same cell type, and ideally same batch. Then, we
generated the expression signature by selecting a set of
up- and down-regulated genes with more than 1.5 fold
change in drug treated cells and then used it to query the
database to search for drugs with a similar expression sig-
nature. First, each instance is tested for similarity with the
query signature. A similarity, or connectivity score is
defined, using a rank-based enrichment method utiliz-
ing the Kolmogorov-Smirnov statistic, which measures
the enrichment of up- and down-regulated genes at the
top and bottom of the ranked gene lists to generate a
score between -1 and +1 [19]. A high positive connectivity
score with the query signature indicates a similar expres-
sion profile has been found. Second, we test whether each
drug represented in the database is significantly enriched
for similarity to the query signature. To do this, all in-
stances in the database are ranked according to their con-
nectivity scores with the query signature. The enrichment
score of a particular drug, with N instances in the data-
base, is calculated using a Kolmogorov-Smirnov statistic,
based on the enrichment of its set of N instances in the
ranked list of all instances. A high enrichment score in-
dicates that the drug induces an expression profile
similar to the query signature. Finally, The significance
of enrichment were accessed using permutation p-value




D00801 Lithium Antidepressant Ion
D00020 Tryptophan Antidepressant Amino acid
D08257 Nefazodone Antidepressant 5-HT2A-receptor antagonist
D00559 Pramipexole hydrochloride Antiparkinsonian with Antidepressant activity Dopamine Agonist
D01164 Aripiprazole Augmentation Agent to other
Antidepressants
Dopamine-serotonin system stabilizer
D07591 Bupropion Antidepressant inhibitor of dopamine and noradrenalin reuptake
D00785 Selegiline hydrochloride Antidepressant monoamine oxidase B inhibitor
D02580 Isocarboxazid Antidepressant monoamine oxidase inhibitor
D08349 Phenelzine Antidepressant
D08456 Quetiapine Augmentation Agent to other
Antidepressants
Multi-acting-receptor-targeting-antipsychotics
D00563 Mirtazapine Antidepressant Noradrenergic and specific serotonergic
antidepressant
D08626 Trazodone Antidepressant Serotonin antagonist and reuptake inhibitor
D05523 Pizotyline Antidepressant Serotonin inhibitor
D01107 Milnacipran hydrochloride Antidepressant Serotonin– noradrenaline reuptake inhibitor
D01179 Duloxetine hydrochloride Antidepressant
D07793 Desvenlafaxine Antidepressant
D08670 Venlafaxine Antidepressant
D00326 Fluoxetine Antidepressant Selective serotonin re-uptake inhibitor
D00824 Fluvoxamine maleate Antidepressant





D00228 Amoxapine Antidepressant Tetracyclic antidepressant
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100,000 sets of N instances selected at random from
the set of all instances in the result.Softwares
The side effect profile similarity analysis were carried
out using R 3.2.0. The similarity networks in Fig. 1 were
generated using Gephi 0.8.2 beta. The connectivity map
analyses were conducted using the online analysis tools
at http://portals.broadinstitute.org/cmap/.Results
Side effect profile similarities between antidepressants
and immunological drugs
Out of the 1005 drugs studied, we identified 27 marketed
antidepressants, 2 drugs (Aripiprazole and Quetiapine)
used as augment to other antidepressants, and 1 drug
(pramipexole) that had shown antidepressive effect but
not approved yet [23] (Table 1). Using these 30 drugs as a
representation of antidepressants, we identified 190 drugs
having side effect profile similarities with 27 antidepres-
sants. Three antidepressants (tryptophan, isocarboxazid
Fig. 1 (See legend on next page.)
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(See figure on previous page.)
Fig. 1 One hundred ninety drugs shared side effect profile similarities with 27 antidepressants in the study. Drugs are represented by dots and
similarities between drugs are represented by edges between dots. The thickness of the edges represents the cosine correlation coefficient as
determined by formula 1, which represents the degree of side effect similarity between drugs. a Different type of antidepressants formed
different clusters according to their side effect profiles. The antidepressants are colored according to their type, while other drugs are colored
yellow. b Anti-inflammatory drugs and immunosuppressants with side effect profile similar to antidepressants. The antidepressants are colored
blue, while other drugs are colored according to their function and/or targets. Drugs that are out of the scope of this study (i.e. not immune
related and have limited evidence of antidepressant-like activities) are colored yellow to simplify the background
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ities with any of the drugs tested in our study. The similar-
ities between these 217 drugs are depicted as a network
shown in Fig. 1, in which each node represents a drug and
edges between the nodes represent pair-wise side effect
similarities, with the thickness of the edge corresponding
to the degree of similarities. As shown in Fig. 1a, different
type of antidepressants formed distinct clusters based on
side effect similarities with each other. Six of the 7 tricyclic
antidepressants (TCA) and 1 tetracyclic antidepressants
(TeCA) formed one cluster, while 5 selective serotonin
re-uptake inhibitors (SSRI) and 4 serotonin-noradrenaline
reuptake inhibitors (SNRI) formed another cluster with no
direct connection with the TCA cluster. Most other anti-
depressants were connected with the SSRI/SNRI cluster
while only 4 antidepressants (trazodone, bupropion, pra-
mipexole, and aripiprazole) shared side effect similarities
with both SSRI/SNRI and TCA. Interestingly, one TCA,
clomipramine, only shared side effect similarities with two
SSRI but no other TCA. Lithium had a unique side effect
profile and showed no significant similarities with any
other antidepressants we studied.
About 48 % of the 190 drugs having side effect simi-
larities with antidepressants have known effects on the
nervous system, including dopamine receptor agonists
and antagonists, GABAA-receptor agonists, μ -opioid
receptor agonists and antagonists, antipsychotics, anti-
migraine, anticonvulsants, and analgesic drugs. Some of
these drugs are already known to have antidepressant
like effects. For example, tramadol, a μ-opioid receptor
agonist used to treat moderate to moderately severe pain,
showed side effect profile similarity with 3 antidepressants:
duloxetine, aripiprazole and bupropion (Fig. 1b) . Tramadol
has long been investigated for its antidepressant effect [24].
A controlled-release formulation of tramadol (ETS6103)
has been developed by e-Therapeutics for treatment of
MDD patients and is currently being tested in clinical
trials. Two glutamate receptor signaling related drugs,
riluzole (a glutamate modulator used to treat amyo-
trophic lateral sclerosis) and lamotrigine (a glutamate
release inhibitor used for treating bipolar disorder), also
showed side effect similarities with multiple antidepres-
sants (Fig. 1b). Both have shown antidepressant-like effects
in animal models and/or open-label studies [25]. Pregaba-
lin, an anticonvulsant drug used for neuropathic pain andlater approved for treating generalized anxiety disorder
(GAD), also showed similarities with multiple antide-
pressants (Fig. 1b). Pregabalin has shown efficacy in
treating depressive symptoms associated with GAD as
well [26].
Of the 1005 drugs we analyzed, 15 were immune-
modulators and 66 were anti-inflammatory drugs. Of
them, 7 immune-modulators and 14 anti-inflammatory
drugs (7 COX inhibitors and 7 glucocorticoids) showed
side effect similarities with antidepressants (Table 2). The
enrichment is significant for the immune-modulators
(Fisher exact test one-sided P-value = 0.015), but not for the
anti-inflammatory drugs (P-value =0.75). Of the 7 COX in-
hibitors, only flurbiprofen had side effect similarities with
more than one antidepressant. Four of the 7 glucocorticoids
(hydrocortisone 17-butyrate, clocortolone, alclometasone
and halcinonide) had side effect similarities with a single
antidepressant, venlafaxine, forming a small cluster on
the side effect similarity network (Fig. 1b). Two other
glucocorticoids (cortisone and hydrocortisone) and one
mentalocorticoid/glucocorticoid (fludrocortisone) had
side effect similarities with lithium. Similar clusters were
also formed by immune-modulator glatiramer acetate
(GA) with 5 antidepressants, and between 4 immune-
modulators and pramipexole. Drugs within these clusters
share some rare side effects. For example, in the cluster
formed by GA and neighboring 5 antidepressants, 10 rare
side effects were shared by greater or equal to 3 drugs in
addition to GA (Table 2). Some of these side effects are re-
lated to immune response (e.g. tenosynovitis which is an
inflammation of the lining of the sheath that surrounds a
tendon, and Rheumatoid arthritis) or mood disorders (e.g.
depressive type psychosis), while others whose underlying
biological processes may be more complicated (e.g. tongue
discoloration).
GA is a random polymer of 4 amino acids (TGAL co-
polymer) found in myelin basic protein. It binds to major
histocompatibility complex II (MHC II) and competes
with myelin antigens for their presentation to T cells. GA
may increase brain-derived neurotrophic factor (BDNF)
expression [27] and reduce P2X7 receptor level [28], both
of which may play important roles in MDD [29, 30]. The
interaction map of GA from Ingenuity shows that proteins
and complexes known to interact with GA directly or in-
directly are highly enriched for genes involved in nervous
Table 2 Drugs with side effect profiles similar to antidepressants








Immune-modulator HLA-DRB1 Multiple sclerosis Fluoxetine SSRI 0.001 Tenosynovitis (6); Skin hypertrophy (5);
Tongue discolouration (5); Alcohol
intolerance (4); Circumoral paresthesia (4);
Dental caries (4); Depressive type psychosis
(4); Rheumatoid arthritis (4); Salivary gland
enlargement (4); Urethritis (4)
Paroxetine SSRI 0.006
Fluvoxamine SSRI 0.001
Selegiline MAO-B inhibitor <0.001
Mirtazapine 5HT & α2-adrenergic
receptor antagonist
<0.001




0.019 Chronic obstructive pulmonary disease (3);
Diverticulitis (3); Ear infection (3) Prostate
cancer (3)
Ustekinumab Immune-modulator Interleukin 12/23 Plaque psoriasis; Psoriatic
arthritis
0.002
Pimecrolimus Immune-modulator Calcineurin Atopic dermatitis <0.001
Siltuximab Immune-modulator Interleukin 6 Castleman’s disease <0.001




Selegiline MAO-B inhibitor 0.016
Montelukast Immune-modulator Cysteinyl leukotriene
receptor 1 (CYSLTR1)





COX-1/2 Inflammations; Pain Paroxetine SSRI 0.006 Bleeding time prolonged (4); Retinal
haemorrhage (4); Fever chills (4); Pyuria (4);
Keratoconjunctivitis (3); WBC abnormal NOS
(3); Tenosynovitis (3) ; Urethritis (3); Deficiency
anaemia (3); Diarrhoea haemorrhagic (3);
Electroencephalogram abnormal (3); Enteritis
(3); Iron deficiency (3); Iron deficiency
anaemia (3)
Ketoprofen Fluoxetine SSRI 0.003
Flurbiprofen Paroxetine SSRI <0.001
Fluoxetine SSRI <0.001
Diclofenac Nefazodone 5HT receptor antagonist 0.037
Rofecoxib COX-2 Duloxetine SNRI 0.029
Meloxicam Clomipramine Non-selective monoamine
reuptake inhibitor (TCA)
0.031
Valdecoxib Sertraline SSRI 0.015




Lithium Other 0.004 Benign intracranial hypertension (4);
Exophthalmos (4); Papilloedema (4);
Pseudotumor (4)
Cortisone Glucocorticoid receptor Inflammations; Pain 0.005





















Skin irritations Venlafaxine SNRI 0.017 Miliaria (5); Skin atrophy (5); Skin striae (5)
Clocortolone 0.012
Alclometasone 0.01
Halcinonide NR3C1 and SMO 0.026
*P-value determined by random shuffling the side effect labels 1000 times and then compares the randomly generated cosine correlation coefficient with the original one
**The top shared rare side effects are the ones that are shared by more than half of the drugs sharing side effect similarity connections within the cluster. Numbers in the parentheses are the number of drugs within
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Fisher Exact test =7.3 E-23).
Four of the 7 immune-modulators had side effect similar-
ities with pramipexole, a dopamine receptor agonist with
antidepressant activity approved for treating Parkinson’s
disease. . These 4 drugs are immune-modulators with dif-
ferent targets: lenalidomide targeting TNF-α, ustekinumab
targeting interleukin 12 and 23, siltuximab targeting inter-
leukin 6 and pimecrolimus inhibiting calcineurin. It has
shown antidepressant activity in multiple controlled clinical
trials as well as open-label studies [23]. Another immune
modulator, montelukast, also showed side effect similarity
with antidepressant targeting the dopamine pathway.
Montelukast is a drug used for treating asthma and sea-
sonal allergies. It showed side effect similarities with
antidepressant bupropion, which is a dopamine and
norepinephrine reuptake inhibitor (Fig. 1b). Montelukast
is a leukotriene receptor antagonist, and has been shown
to be associated with possible increase in suicidal behavior
and depression [31].
Rapamycin showed side effect similarity with anti-
depressant selegiline (Fig. 1). Rapamycin is used as an
immunosuppressant to prevent rejection after organ
transplant. It inhibits mTOR (mechanistic Target of
Rapamycin), which is involved in translation control and
long-term synaptic plasticity [32]. Recent studies showed
that chronic partial inhibition of mTOR by rapamycin
reduce anxiety and depressive-like behavior in mice,
possibly by stimulating major monoamine pathways
[33], whereas intracerebroventricular infusion of rapa-
mycin could inhibit the rapid antidepressant activity of
ketamine [34].
Connectivity map analysis
Similarities in gene expression profiles of human cells
treated with bioactive small molecules has also been
explored as a method for identifying drugs sharing
common mechanism of action [19]. To further explore
the relationship between drugs included in our study,
we queried the Connectivity Map (CMAP) database for
our 7 immune-modulators and 14 anti-inflammatory drugs.
Of the 7 immune-modulators, only rapamycin (Sirolimus)
had expression profiles in CMAP. There are 44 “instances”
in CMAP recording the changes in different human cell
lines induced by rapamycin. Each instance contains a
treated and control cell pair. To reduce the influence of ex-
perimental batch and cell lines, we selected instances from
the same batch and cell lines and generated the expression
signatures by selecting the genes that showed at least 1.5
fold of change between cells treated with rapamycin and
control cells. These generated 12 rapamycin expression
profiles from 36 CMAP instances. Each expression profile
contains a list of up/down regulated genes in the rapamycin
treated cell lines. We then queried the database for drugswith similar expression profiles to these 12 rapamycin pro-
files using the pattern-matching tool provided by CMAP.
Two profiles from PC3 cells and 5 profiles from MCF7 cells
treated with rapamycin were similar to profiles of 2 types of
antidepressants (permutation p-value of enrichment <0.05):
non-selective monoamine reuptake inhibitors such as clo-
mipramine, amoxapine, protriptyline, maprotiline, desipra-
mine, nortriptyline, trimipramine, and amitriptyline; and
selective serotonin reuptake inhibitors such as zimelidine
and fluoxetine (Table 3). However, 3 profiles from HL60
cells and 2 profiles from MCF7 cells treated with rapamycin
did not show similarities with antidepressants. The same
query was conducted for the 14 anti-inflammatory drugs.
All except 2 (meloxicam and clocortolone) had instances in
CMAP database. Of them, alclometasone showed ex-
pression similarities with antidepressants fluvoxamine
and citalopram (Table 4).
Discussion
In this study, we’ve explored the space of drug side effect
profile similarities between immune-modulators/anti-in-
flammatory medications and antidepressants. Side effect
profiles contain complex phenotypic information related
to the underlying physiological pathways affected by
medications. Similarities in side effect profiles indicate
that drugs share common targets or off-targets, or perturb
common downstream pathways. Thus this could provide
us new insights as to how the immune system may influ-
ence mood and vice versa. The immune-modulators and
anti-inflammatory drugs sharing side effects with antide-
pressants in our study fall into two different categories:
one targeting pathways such as glucocorticoid signaling,
which is known to affect both immune and nervous
systems; the other targeting mainly pro-inflammatory
mediators such as cytokines, TNF-α and calcineurin,
which may then influence the nervous system through
a bidirectional communication route between the immune
and the nervous system.
Four glucocorticoids showed side effect similarity with
antidepressant venlafaxine while another three showed
similarity with lithium in our study. One of them, alclo-
metasone induced expression profiles in human cells
similar to that induced by antidepressants fluvoxamine
and citalopram, suggesting that glucocorticoids and anti-
depressants may induce common molecular pathways.
Glucocorticoids exert their anti-inflammatory effect by
binding to glucocorticoid receptor (GR), which then
suppress the transcription of pro-inflammatory cytokines
such as IL-6, IL-12, COX-2 and TNFα [35]. GR has also
been proposed to play pivotal role in depression and
antidepressant treatment [36]. Under normal physio-
logical conditions, glucocorticoid activated GR mediates
a negative feedback loop to maintain low glucocorticoid
levels in the brain. However, this negative feedback loop
Table 3 CMAP expression signature similarities between human cells treated with rapamycin and antidepressants
CMAP
Instancea

























MCF7 27 56 desipramine non-selective monoamine
reuptake inhibitors
0.01156 0.724



























MCF7 25 60 amitriptyline non-selective monoamine
reuptake inhibitors
0.01422 0.596
aThe ID of the instances from CMAP database used to generate the query expression signature for rapamycin
bNumber of up and down regulated probes of the querying expression signature determined after 1.5 fold change in expression level between drug-treated cells
and control cells
cA measure of the enrichment of the instances for antidepressant in the list of all instances ordered by expression profile similarity score
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high levels of glucocorticoids and constant hyperactivity of
the hypothalamus-pituitary-adrenal (HPA) axis [37]. Studies
in rodent models have shown that chronic glucocorticoid
treatment induces depression and anxiety-like behavior,
and reduction of adult hippocampal neurogenesis [38].
Treatment with antidepressants could normalize HPA
axis hyperactivity, possibly by restoring GR function
[36]. Interestingly, glucocorticoids such as prednisolone,
dexamethasone and cortisol have been reported to have
antidepressant-like effects in MDD patients, possibly
by restoring the negative feedback loop on the HPA
axis [39–41]. Taken together, these suggest that the
glucocorticoid receptor is involved in both immune
regulation and depression, and may be a viable target for
treating depressed patients with HPA axis hyperactivity.Table 4 CMAP expression signature similarities between human cel
CMAP
instance









Alclometasone MCF7 58 35 fluv
citaAnother example is glatiramer acetate (GA), which has
a dual anti-inflammatory and neuroprotective role in
treating multiple sclerosis (MS) [42]. GA is a synthetic
polypeptide mixture containing amino acids glutamic
acid, lysine, alanine and tyrosine in a molar ratio of 1.4 :
3.4: 4.2 : 1.0 assembled in a random order into polypep-
tide chains with 40 ~ 100 amino acids [43]. Peripheral
GA treatment (either by subcutaneous injections or by
oral administration) induces GA-specific T cells in the
peripheral immune system, which can cross the blood
brain barrier to accumulate in the CNS. These T cells are
type 2 T helper (Th2) cells that secrete anti-inflammatory
cytokines such as IL-4, IL-10 and TGF-β, thus blocking
the immune response in the CNS. In addition, Th2 cells
also produce neurotrophic factors such as BDNF, which
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induced a “bystander effect” on CNS resident cells to pro-
duce anti-inflammatory cytokines and neurotrophic factors
[43]. It is interesting to observe that among the immune-
modulators we studied, GA is the only one that shows side
effect profile similarity with multiple antidepressants. How-
ever, it is unknown to us whether these similarities were
the result of anti-inflammatory effect of GA or its neuro-
protective effect, or both. Because antidepressant treatment,
like GA, can also restore the decreased BDNF function in
MDD patients up to the normal level [45]. According to
this evidence, the dual effect of GA treatment may also
benefit patients with depressive symptoms and is worth
further study.
Rapamycin, also known as sirolimus, may also have
dual functions regulating both the immune and nervous
system. Rapamycin forms a complex with FK-binding
protein 12 (FKBP12) and then inhibits the mTOR pathway
by binding directly to mTOR complex 1. The mTOR
pathway is involved in both immune response regulation
[46] and synaptic plasticity [47] by acting as a bridge
between extracellular signals and translation machinery.
Inhibition of mTOR by rapamycin can block the response
to IL-2, thus suppressing immune system. Interestingly,
blocking the mTOR pathway by intracerebroventricular
infusion of rapamycin could inhibit the rapid antidepres-
sant activity of ketamine [34], whereas chronic and partial
inhibition of mTOR by rapamycin could reduce anxiety
and depressive-like behavior in mice throughout their
lifespan, possibly by stimulating the production of
major monoamines (norepinephrine, dopamine and 5-
hydroxytrptamine) [33]. Our study showed that at both
the clinical level and cellular level, rapamycin shared
phenotypic similarities with antidepressants targeting
monoamines: monoamine oxidase B (MAO-B) inhibitor,
selegiline, which prevents the breakdown of monoamines;
as well as monoamine reuptake inhibitors, which helps in-
crease the extracellular concentrations of the monoamine
neurotransmitters. Besides the regulation of monoamine
levels, another possible link between MAO-B activity and
rapamycin is mitochondria turnover. One study has found
that age or neurodegenerative disorder related brain
MAO-B level elevation could contribute to the accumula-
tion of damaged mitochondrial and neurodegeneration.
Treatment by rapamycin could counteract this process by
enhancing autophagic removal of damaged mitochondria
[48]. Based on current knowledge, the immune suppres-
sant activity and antidepressant-like activity of rapamycin
may both depend on its ability to inhibit the mTOR path-
way. Further analyses are needed to reveal whether the
antidepressant-like activity of rapamycin is dependent on
its immune suppressant activity.
In our study, most of the immune-modulators sharing
side effect profile similarities with antidepressants donot seem to have dual functions like GA and rapamycin.
They suppress the immune response by targeting pro-
inflammatory mediators. These immune-modulators had
side effect profiles similar to antidepressants targeting
the dopamine pathway. Four of them had side effect
similarities with Pramipexole, a dopamine receptor agonist
with antidepressant-like activity. Another drug, montelu-
kast, a leukotriene receptor antagonist, showed side effect
similarities with antidepressant bupropion, which is a
norepinephrine-dopamine reuptake inhibitor. Dopamine
has been proposed as one of the key neurotransmitters
bridging the nervous and immune systems, since dopa-
mine and its receptor are expressed not only by the central
and peripheral nervous cells, but also by different immune
cells [49]. Communication between CNS and the per-
ipheral immune system may be carried out by dopamine
activated T cells crossing the blood brain barrier [50].
A recent study showed that electroacupuncture at the
sciatic nerve of mice could induce dopamine production
in the adrenal medulla, which then leads to the inhibition
of cytokine production by dopamine, confirming the
dopaminergic regulation of immune response [51]. Inter-
estingly, studies have shown that changes in the expres-
sion of dopamine receptors and their signaling pathways,
especially in T cells, are associated with altered immune
functions in schizophrenia and Parkinson’s disease
[52, 53]. The similarities in the side effect profiles as
observed by us may be a reflection of the communication
between immune system and nervous system through
dopamine. Even though deficiencies in dopamine, sero-
tonin and noradrenaline are thought to underpin MDD
pathophysiology, treating MDD with drugs targeting
dopamine pathway is under-recognized currently [54].
Considering the role that dopamine plays in both mood
and immune response, it may provide viable treatment op-
tions for MDD patients who are resistant to treatments
with SSRI, and who have elevated immune activation, per-
haps indicated by CRP levels.
Like dopamine, serotonin has also been shown to be
able to act as signaling agents between immune cells,
helping to enhance T cell activation [55, 56]. There is
also evidence supporting that CNS serotonin neurons
are direct or indirect targets for the communication
from the immune system to the brain via both humoral
and neuronal mechanisms [57]. The pro-inflammatory
cytokine IL-1β could increase extracellular levels of sero-
tonin in the brain as well as serotonin transporter
(SERT) activity, which may reflect a coordinated seroto-
nergic response to immune activation, and disruption of
this homeostatic mechanism may be a risk for diseases
such as depression or autism [57]. Seven COX inhibitors
in our study showed side effect similarities with antide-
pressants, which targets the serotonin signaling (Table 2).
Our results seem to indicate that COX inhibitors targeting
Sun et al. BMC Pharmacology and Toxicology  (2016) 17:47 Page 12 of 14the synthesis of prostanoids and immune-modulators tar-
geting other pro-inflammatory mediators may interact
with nervous systems through different communication
routes. Whether this is related to differences between the
serotonergic and dopaminergic systems needs further
explorations.
Interestingly, studies have shown that antidepressants
also have anti-inflammatory effects, possibly through in-
creasing production of IL-10 [58] and suppressing the
expression of TNF-α and IL-6 [59]. This is consistent
with our findings that antidepressants and immune-
modulators may affect similar molecular mechanisms
and thus share common physiological effects, and further
supports the idea that serotonin and other monoamines
targeted by antidepressants may play an important role in
the communication between the immune and nervous sys-
tem. Several immune-modulators and anti-inflammation
medications have also shown antidepressant-like effects
[14]. For example, IL-12/23 inhibitor ustekinumab im-
proves symptoms of depression and anxiety in patients with
psoriasis [10]. COX 2 inhibitors such as celecoxib have
been reported to benefit MDD patients when used together
with other antidepressants but not when using alone
[11, 13]. TNF-α inhibitor infliximab could reduce de-
pressive symptoms in treatment-resistant MDD patients
having relatively more severe inflammation symptoms [9].
In our analysis, ustekinumab showed side effect similar-
ities with antidepressants, but celecoxib and infliximab did
not. This could mean that antidepressants in our study
share limited common molecular mechanisms with cele-
coxib and infliximab. But it could also due to incomplete
side effect profiles captured by the drug labels of these
drugs. Even though we analyzed the side effects of over
1000 drugs, it is by no means a comprehensive survey of
all marketed drugs. Additional similarities between antide-
pressants and immune related medications may be re-
vealed with a bigger drug-side effect database. A more
comprehensive survey of the side effects reported from
more patients such as those stored in the FDA adverse
reporting system may help resolve this question in the fu-
ture. Another approach is to extend the side effect profiles
using in silico side effect prediction methods based on cor-
relation between side effect and drug structure [60] or
based on predicted interactions between drugs and key
metabolic enzymes such as cytochrome P450 [61].The
value of repurposing drugs has to be explored in the con-
text of the side-effect risk associated with the repurposed
compound; for example biologics are often associated with
higher risk of infections, such as pneumonia [62]; there-
fore the value proposition for the patient would be based
on having failed to respond to safer compounds, and
ideally the ability to enrich for patients likely to respond.
Identifying that cohort is beyond the scope or capability of
this study, but an essential next step. Nevertheless, resultsfrom our side-effect profile similarities suggest that the
antidepressant potential of several novel candidates such
as Siltuximab and Pimecrolimus may worth further ex-
ploration, as may the re-evaluation of dopaminergic anti-
depressants among MDD patients with high levels of
inflammation.
Conclusions
Our analysis of drug-similarity based on side effect profiles
indicates that some antidepressants and some immune-
related drugs may affect common molecular pathways.
This may result from the immune-modulators affecting
mood directly through the drugs intended target, indir-
ectly through downstream effects on serotonin and/or
dopamine pathways, or through novel mechanisms not
yet understood. Our findings support the idea that certain
medications aimed at the immune system may be helpful
in relieving depressive symptoms, and suggest that it may
be of value to test immune-modulators, such as rapamycin
and alclometasone, for antidepressant-like activity in fu-
ture proof-of-concept studies. Our results also support the
hypothesis that both dopamine and serotonin may play
critical roles in the communications between immune and
CNS systems. For MDD patients who fail to respond to
treatment with antidepressants aiming at the serotonergic
pathway, compounds targeting the dopaminergic pathway
may provide new choices for the subset of patients with
an inflammatory diathesis. Side effect profile based drug-
drug similarity is particularly informative, since side effect
profile is derived from drug intervention in human. How-
ever, this metric provides only one view of the crosstalk
between depression and immune response. Therefore, to
further clarify the mechanistic similarities between antide-
pressants and drugs targeting the immune response sys-
tem, analysis of additional drug similarity metrics base
on drug structure, treatment elicited gene expression
signatures, pathway enrichment, and protein-protein
interaction networks are needed. These data may in-
form novel mechanisms and identify new targets for
antidepressant effects, and may aid in the prioritization
process for designing more direct proof-of-concept studies.
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